Researchers from Beijing Inno Medicine Co. Ltd. recently reported preclinical data for the novel liposome encapsulated rosuvastatin calcium candidate, YN-001, being developed for the treatment of atherosclerosis.

Noetik Inc. has closed an oversubscribed $14 million seed financing round. The company has built a multimodal tissue profiling platform that combines self-supervised learning with spatial biology to tackle problems in cancer immunology.

Carrick Therapeutics Ltd. has received FDA clearance of its IND application for CT-7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.

Artelo Biosciences Inc. has completed a pre-IND meeting with the FDA regarding the manufacturing, preclinical and clinical development plan for ART-26.12.

Researchers from the Royal Melbourne Hospital and Peter MacCallum Cancer Centre, along with other affiliated organizations, have published details on the synthesis and in vivo characterization of a novel series of 177Lu-labeled peptides with strong binding affinity to the cholecystokinin CCK2 receptor, an important molecular target which is highly expressed in a range of cancers.

Proteros Biostructures GmbH has established a new collaboration with Orion Corp. The two companies are engaging in a joint multitarget collaboration for early-stage drug discovery projects in oncology and pain using Proteros’ discovery platform, and now have decided to combine their expertise to assemble a chemically diverse small-molecule library collection. The nonexclusive agreement enables Proteros to exclusively offer access to this high throughput screening (HTS) library to all its clients.